CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors' preferences ("Prometheus") in Russia - first results of the survey

• Main Authors: E. V. Artamonova (Author), E. I. Kovalenko (Author), L. V. Bolotina (Author), M. B. Stenina (Author), R. V. Orlova (Author), M. A. Mukhina (Author)
• פורמט: ספר
• יצא לאור: ABV-press, 2021-01-01T00:00:00Z.
• נושאים: article
• גישה מקוונת: Connect to this object online.

The emergence of a new class of drugs - inhibitors of cyclin-dependent kinases 4/6 (CDK4/6) - has changed the paradigm of treatment of patients with luminal HER2 negative metastatic breast cancer. Their effectiveness is confirmed not only by randomized, but also observational studies on a wide heter...